UK experience of Ofatumumab in refractory B-CLL by Varghese, A, Pattinson, J, Carrington, P, Bloor, A, Follows, G, Hillmen, P, Schuh, A, Chowdhury, O

Ofatumumab in advanced stage chronic lymphocytic leukaemia: results of the UK named patient compassionate use programme. by Chowdhury, O, Varghese, A, Pattinson, J, Carrington, P, Bloor, A, Follows, G, Hillmen, P, Schuh, A

Profile of Steroid Toxicity During Maintenance Treatment in Teenage and Young Adult (TYA) Patients with Acute Lymphoblastic Leukaemia (ALL) by Tomlins, J, Kulkarni, S, Rowntree, C, Goulden, N, Mitchell, C, Hough, R, Richards, S, Clack, R, Bloor, A, Vora, A

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma. by Eyre, T, Osborne, W, Gallop-Evans, E, Ardeshna, K, Kassam, S, Sadullah, S, Sidra, G, Culligan, D, Arumainathan, A, Shankara, P, Bowles, K, Eyre, D, Peng, Y, Pettengell, R, Bloor, A, Vandenberghe, E, Collins, G

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Roberts, C, Love, S, Eyre, T, Clifford, R, Boyle, L, Cabes, M, Schuh, A, Bloor, A, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, McCarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamopoulos, B, Weatherspoon, A

NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome by Eyre, T, Clifford, R, Bloor, A, Boyle, L, Roberts, C, Cabes, M, Collins, G, Devereux, S, Follows, G, Fox, C, Gribben, J, Hillmen, P, Hatton, C, Littlewood, T, Mccarthy, H, Murray, J, Pettitt, A, Soilleux, E, Stamatopoulos, B, Love, S, Wotherspoon, A, Schuh, A

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. by Chakraverty, R, Orti, G, Roughton, M, Shen, J, Fielding, A, Kottaridis, P, Milligan, D, Collin, M, Crawley, C, Johnson, P, Clark, A, Parker, A, Bloor, A, Pettengell, R, Snowden, J, Pettitt, A, Clark, R, Hale, G, Peggs, K, Thomson, K, Morris, E, Mackinnon, S

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the... by Pettitt, A, Jackson, R, Carruthers, S, Dodd, J, Dodd, S, Oates, M, Johnson, G, Schuh, A, Matutes, E, Dearden, C, Catovsky, D, Radford, J, Bloor, A, Follows, G, Devereux, S, Kruger, A, Blundell, J, Agrawal, S, Allsup, D, Proctor, S, Heartin, E, Oscier, D, Hamblin, T, Rawstron, A, Hillmen, P